Raymond James & Associates Alkermes Plc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Alkermes Plc. stock. As of the latest transaction made, Raymond James & Associates holds 18,224 shares of ALKS stock, worth $523,940. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,224

Previous 19,097 4.57%

Holding current value

$523,940

Previous $460,000 10.87%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$23.01 - $28.55 $20,087 - $24,924	-873 Reduced 4.57%	18,224 $510,000
Q2 2024 Jul 19, 2024	BUY	$23.21 - $27.24 $16,479 - $19,340	710 Added 3.86%	19,097 $460,000
Q1 2024 Apr 22, 2024	BUY	$26.4 - $32.56 $12,408 - $15,303	470 Added 2.62%	18,387 $497,000
Q4 2023 Jan 16, 2024	SELL	$23.37 - $28.68 $202,734 - $248,799	-8,675 Reduced 32.62%	17,917 $497,000
Q3 2023 Oct 24, 2023	BUY	$27.17 - $31.97 $176,876 - $208,124	6,510 Added 32.42%	26,592 $744,000
Q2 2023 Jul 25, 2023	BUY	$28.34 - $33.63 $15,700 - $18,631	554 Added 2.84%	20,082 $628,000
Q1 2023 Apr 14, 2023	SELL	$25.31 - $29.02 $8,959 - $10,273	-354 Reduced 1.78%	19,528 $550,000
Q4 2022 Feb 08, 2023	SELL	$21.94 - $26.24 $107,154 - $128,156	-4,884 Reduced 19.72%	19,882 $519,000
Q3 2022 Oct 25, 2022	SELL	$22.0 - $31.87 $48,840 - $70,751	-2,220 Reduced 8.23%	24,766 $553,000
Q2 2022 Aug 12, 2022	SELL	$26.4 - $30.54 $152,512 - $176,429	-5,777 Reduced 17.63%	26,986 $804,000
Q1 2022 May 11, 2022	BUY	$23.07 - $27.99 $430,647 - $522,489	18,667 Added 132.43%	32,763 $862,000
Q4 2021 Feb 08, 2022	SELL	$21.47 - $32.08 $35,081 - $52,418	-1,634 Reduced 10.39%	14,096 $328,000
Q3 2021 Nov 02, 2021	BUY	$23.37 - $32.13 $162,608 - $223,560	6,958 Added 79.32%	15,730 $485,000
Q2 2021 Aug 11, 2021	BUY	$18.78 - $25.15 $164,738 - $220,615	8,772 New	8,772 $215,000
Q4 2018 Feb 11, 2019	SELL	$27.94 - $44.61 $699,366 - $1.12 Million	-25,031 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $12,120 - $14,481	314 Added 1.27%	25,031 $1.06 Million
Q2 2018 Aug 14, 2018	SELL	$40.56 - $51.36 $431,639 - $546,573	-10,642 Reduced 30.1%	24,717 $1.02 Million
Q1 2018 May 14, 2018	BUY	$53.61 - $67.26 $552,343 - $692,979	10,303 Added 41.12%	35,359 $2.05 Million
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $3,576 - $4,154	-75 Reduced 0.3%	25,056 $1.37 Million
Q3 2017 Nov 13, 2017	BUY	$49.16 - $54.45 $34,903 - $38,659	710 Added 2.91%	25,131 $1.28 Million
Q2 2017 Aug 14, 2017	BUY	N/A	24,421	24,421 $1.42 Million

Others Institutions Holding ALKS

# of Institutions

363

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.72B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Alkermes Plc. Transaction History